CIK 1458461
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2021-Q2. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 59.66% | 8 |
| Unclassified | 40.34% | 10 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | GILD | GILEAD SCIENCES, INC. | Health Care | 10.88% |
| 2 | GLAXOSMITHKLINE PLC | Unclassified | 9.92% | |
| 3 | PFE | PFIZER INC | Health Care | 8.37% |
| 4 | ALKS | Alkermes plc. | Health Care | 8.00% |
| 5 | AMRYT PHARMA PLC | Unclassified | 7.85% | |
| 6 | MRK | Merck & Co., Inc. | Health Care | 7.80% |
| 7 | AZN | Astrazeneca PLC | Health Care | 7.79% |
| 8 | BMY | BRISTOL MYERS SQUIBB CO | Health Care | 7.68% |
| 9 | IRWD | IRONWOOD PHARMACEUTICALS INC | Health Care | 6.78% |
| 10 | CLOVIS ONCOLOGY INC | Unclassified | 5.79% |
8/18 names classified · sector 59.7% of weight · industry 59.7% · mkt cap 51.9%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 59.7% of the book is sector-classified (unclassified names shown, never dropped).
Classified: 51.9% of book weight (7/9 names) · unclassified 48.1%: , AZN. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | GILDGILEAD SCIENCES INC | 60,000 | $4M | 10.9% | TRIM −20% |
| 2 | GLAXOSMITHKLINE PLC | 100,000 | $4M | 9.9% | HOLD |
| 3 | PFEPFIZER INC | 75,000 | $3M | 8.4% | TRIM −25% |
| 4 | ALKSALKERMES PLC | 100,000 | $3M | 8.0% | TRIM −33% |
| 5 | AMRYT PHARMA PLC | 250,000 | $3M | 7.8% | ADD 25% |
| 6 | MRKMERCK & CO INC | 40,000 | $3M | 7.8% | HOLD |
| 7 | AZNASTRAZENECA PLC | 50,000 | $3M | 7.8% | HOLD |
| 8 | BMYBRISTOL-MYERS SQUIBB CO | 50,000 | $3M | 7.7% | HOLD |
| 9 | IRWDIRONWOOD PHARMACEUTICALS INC | 200,000 | $3M | 6.8% | HOLD |
| 10 | CLOVIS ONCOLOGY INC | 500,000 | $2M | 5.8% | HOLD |
| 11 | TYME TECHNOLOGIES INC | 2,000,000 | $2M | 5.3% | ADD 33% |
| 12 | ANTARES PHARMA INC | 500,000 | $2M | 4.7% | HOLD |
| 13 | VRTXVERTEX PHARMACEUTICALS INC | 5,000 | $907,000 | 2.4% | NEW |
| 14 | GREENLANE HLDGS INC | 350,000 | $830,000 | 2.2% | HOLD |
| 15 | VYNE THERAP. | 400,000 | $556,000 | 1.4% | TRIM −11% |
| 16 | ADAMAS PHARMACEUTICALS INC | 100,000 | $491,000 | 1.3% | HOLD |
| 17 | GAMIDA CELL LTD | 100,000 | $392,000 | 1.0% | ADD 33% |
| 18 | Durect Corp | 250,000 | $320,000 | 0.8% | NEW |
Where this firm's principals came from and which firms its alumni went on to found.
